ClinicalTrials.gg
CompletedNCT02581865Updated May 7, 2020Results posted

Safety and Efficacy Study of NBI-98854 in Adults With Tourette Syndrome

A Phase 2 interventional study of NBI-98854 and Placebo in Tourette Syndrome, sponsored by Neurocrine Biosciences. Completed at 30 sites in United States. Open to participants aged 18 Years to 64 Years. Per ClinicalTrials.gov, last updated 2020-05-07.

Sponsored by Neurocrine Biosciences · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
124
Allocation
Randomized
Ages
18 Years to 64 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 139 studies in Tourette Syndrome with a site in United States — 20 open to participants now, 24 under way, 1 of them phase 3. Tourette Syndrome · United States.

Enrollment
20th of 105
124 · median 33
Started
2015
with 4 others
Phase 2
26 of 139
4 open now
Registered
72nd of 139
by date
Lead sponsor
8 of 139
Neurocrine Biosciences

Among the 139 studies in Tourette Syndrome with a site in United States, this one is the 20th largest by enrollment of the 105 interventional ones that give a count, is one of 5 that started in 2015, is one of 26 in phase 2, and was the 72nd registered.

Tourette Syndrome

240 studies on the registry are indexed under Tourette Syndrome; 40 are open to participants now.

Browse Tourette Syndrome studies →

Open to participants now

20 of the 139 studies in Tourette Syndrome with a site in United States are open now. Recruiting first, the newest first:

15 more — sign in →

All 20 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 33 Tourette Syndrome studies recruiting now, 9 (27%) set no upper age limit and 22 (67%) stop at 75 or younger; 20 take children under 18; 9 take healthy volunteers.

This study: 18 Years to 64 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 139 studies in Tourette Syndrome with a site in United States, or all of them as a file.
02

Study summary

Phase 2, double-blind, placebo-controlled study to assess the safety and efficacy of NBI-98854 administered once daily (qd) for a total of 8 weeks of treatment. This study will enroll approximately 90 male and female subjects clinically diagnosed with Tourette Syndrome.

03

Conditions studied

  • Tourette Syndrome

Browse trials for

04

Who can participate

Ages eligible
18 Years to 64 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Have a clinical diagnosis of Tourette Syndrome (TS)
  2. Have at least moderate tic severity
  3. Have TS symptoms that impair school, occupational, and/or social function
  4. If using maintenance medication(s) for TS or TS spectrum diagnoses (e.g. obsessive-compulsive disorder [OCD], Attention-Deficit Hyperactivity Disorder [ADHD]), be on stable doses
  5. Be in good general health
  6. Have a negative urine drug screen for amphetamines, barbiturates, benzodiazepine, phencyclidine, cocaine, or opiates, and a negative alcohol screen
  7. Subjects of who do not practice total abstinence must agree to use hormonal or two forms of nonhormonal (dual contraception) consistently during the screening, treatment and follow-up periods of the study

Exclusion criteria

Exclusion Criteria:

  1. Have an active, unstable medical condition within 1 month prior to screening
  2. Have a known history of long syndrome or cardiac tachy-arrhythmia
  3. Have a known history of neuroleptic malignant syndrome
  4. Have a cancer diagnosis within 3 years prior to screening (some exceptions allowed)
  5. Have an allergy, , or intolerance to VMAT2 inhibitors
  6. Have a known history of substance dependence, substance (drug) or alcohol abuse
  7. Have a significant risk of suicidal or violent behavior
  8. Are currently pregnant or breastfeeding
  9. Have initiated Comprehensive Behavioral Intervention for Tics (CBIT) during the screening period or at baseline or plan to initiate CBIT during the study
  10. Have received an drug within 30 days before screening or plan to use an investigational drug (other than NBI-98854) during the study
  11. Have a blood loss ≥550 mL or donated blood within 30 days prior to screening
Terms in these criteria, in plain language(6)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
124 participants (actual)

Study arms

  • Placebo comparator
    Placebo

    Placebo administered once daily for 8 weeks

    Drug: Placebo

  • Experimental
    Dose Group 1

    Fixed dose administered once daily for 8 weeks

    Drug: NBI-98854

  • Experimental
    Dose Group 2

    Fixed dose administered once daily for 8 weeks

    Drug: NBI-98854

Interventions

06

What researchers measure

Primary outcomes

  1. Change From Baseline to Week 8 in the YGTSS TTS

    The YGTSS is designed to rate the overall severity of motor and phonic tic symptoms across a range of dimensions: number, frequency, intensity, complexity, and interference. The YGTSS was administered by the investigator (or qualified designee) using a computer-based structured clinical interview. The TTS is the sum of the 5 motor tic items and the 5 phonic (vocal) tic items and ranges from 0 to 50, with higher scores representing greater severity

    Time frame: Baseline, Week 8

Secondary outcomes

  1. Clinical Global Impression of Change Tourette Syndrome (CGI-TS)-Improvement Score at Week 8

    The CGI-TS-Improvement scale is used to assess overall improvement since the initiation of study drug dosing on a 7-point scale. Each of the CGI-TS-Improvement response categories was assigned a numerical score as follows: 1 = Very much improved; 2 = Much improved; 3 = Minimally improved; 4 = Not changed; 5 = Minimally worse; 6 = Much worse; 7 = Very much worse.

    Time frame: Week 8

  2. Change From Baseline to Week 8 in the Clinical Global Impression of Tics (CGI-Tics)-Severity Score

    The CGI-Tics-Severity scale is used to assess overall severity on a 7-point scale. Each of the CGI-Tics-Severity response categories was assigned a numerical score as follows: 1 = Normal, not at all ill; 2 = Borderline ill; 3 = Mildly ill; 4 = Moderately ill; 5 = Markedly ill; 6 = Severely ill; 7 = Among the most extremely ill patient.

    Time frame: Baseline, Week 8

  3. Change From Baseline to Last Visit in the Rush Video-based Tic Rating Scale (RTRS) Total Score

    A modified RTRS was used in this study that includes short video recordings to measure 5 tic variables: number of body areas affected, frequency of motor and phonic tics, and severity of motor and phonic tics. The RTRS total score is calculated as the sum of the 5 domain scores, and ranges from 0 to 20, with higher scores representing greater severity. The final on-treatment visit was used in subjects who discontinued prior to Week 8.

    Time frame: Baseline, Week 8

  4. Change From Baseline to Week 8 in the YGTSS Global Tic Severity Score

    The YGTSS Global Tic Severity score is the sum of the YGTSS TTS and the YGTSS Impairment score and ranges from 0 to 100, with higher scores representing greater severity.

    Time frame: Baseline, Week 8

  5. Change From Baseline to Week 8 in the Premonitory Urge for Tics Scale (PUTS) Total Score

    The PUTS is an instrument for quantifying the premonitory urge phenomena associated with tics. It consists of 9 items, each of which is scored on a 4-point scale (1=not at all true, 2=a little true, 3=pretty much true, 4=very much true). The PUTS total score is calculated as the sum of the scores for the 9 items. The maximum possible total score is 36.

    Time frame: Baseline, Week 8

07

Results

Posted May 7, 2020

Participant flow

This study enrolled participants (male and female) with a diagnosis of Tourette Syndrome through Diagnostic and Statistical Manual of Mental Disorders, 4th or 5th Editions (DSM-IV or -V) from approximately 40 study centers in the United States

Participant flow — Overall Study
MilestonePlaceboNBI-98854 40 mgNBI-98854 80 mg
Started404242
Completed363526
Not completed4716

Outcome measures

PrimaryChange From Baseline to Week 8 in the YGTSS TTS

The YGTSS is designed to rate the overall severity of motor and phonic tic symptoms across a range of dimensions: number, frequency, intensity, complexity, and interference. The YGTSS was administered by the investigator (or qualified designee) using a computer-based structured clinical interview. The TTS is the sum of the 5 motor tic items and the 5 phonic (vocal) tic items and ranges from 0 to 50, with higher scores representing greater severity

Time frame:
Baseline, Week 8
Reported as:
Least squares mean · Least Squares Mean (Standard Error)
Change From Baseline to Week 8 in the YGTSS TTS
Least Squares Mean (Standard Error)PlaceboNBI-98854 40 mgNBI-98854 80 mg
Change From Baseline to Week 8 in the YGTSS TTS-6.1 ± 1.1-7.4 ± 1.7-8.0 ± 1.1
Statistical analysis
  • Placebo vs NBI-98854 40 mg · Mixed Models Analysis · p = 0.4326 · Mean difference (net): -1.4 · 95% CI -4.9 to 2.1
  • Placebo vs NBI-98854 80 mg · Mixed Models Analysis · p = 0.1835 · Mean difference (net): -2.5 · 95% CI -6.2 to 1.2
SecondaryClinical Global Impression of Change Tourette Syndrome (CGI-TS)-Improvement Score at Week 8

The CGI-TS-Improvement scale is used to assess overall improvement since the initiation of study drug dosing on a 7-point scale. Each of the CGI-TS-Improvement response categories was assigned a numerical score as follows: 1 = Very much improved; 2 = Much improved; 3 = Minimally improved; 4 = Not changed; 5 = Minimally worse; 6 = Much worse; 7 = Very much worse.

Time frame:
Week 8
Reported as:
Least squares mean · score on a scale
Clinical Global Impression of Change Tourette Syndrome (CGI-TS)-Improvement Score at Week 8
score on a scalePlaceboNBI-98854 40 mgNBI-98854 80 mg
Clinical Global Impression of Change Tourette Syndrome (CGI-TS)-Improvement Score at Week 83.2 ± 0.23.0 ± 0.22.6 ± 0.1
Statistical analysis
  • Placebo vs NBI-98854 40 mg · ANOVA · p = 0.3812 · Mean difference (net): -0.2 · 95% CI -0.7 to 0.3
  • Placebo vs NBI-98854 80 mg · ANOVA · p = 0.0146 · Mean difference (net): -0.7 · 95% CI -1.2 to -0.1
SecondaryChange From Baseline to Week 8 in the Clinical Global Impression of Tics (CGI-Tics)-Severity Score

The CGI-Tics-Severity scale is used to assess overall severity on a 7-point scale. Each of the CGI-Tics-Severity response categories was assigned a numerical score as follows: 1 = Normal, not at all ill; 2 = Borderline ill; 3 = Mildly ill; 4 = Moderately ill; 5 = Markedly ill; 6 = Severely ill; 7 = Among the most extremely ill patient.

Time frame:
Baseline, Week 8
Reported as:
Least squares mean · score on a scale
Change From Baseline to Week 8 in the Clinical Global Impression of Tics (CGI-Tics)-Severity Score
score on a scalePlaceboNBI-98854 40 mgNBI-98854 80 mg
Change From Baseline to Week 8 in the Clinical Global Impression of Tics (CGI-Tics)-Severity Score-0.8 ± 0.2-1.0 ± 0.2-1.0 ± 0.1
Statistical analysis
  • Placebo vs NBI-98854 40 mg · Mixed Models Analysis · p = 0.3065 · Mean difference (net): -0.2 · 95% CI -0.6 to 0.2
  • Placebo vs NBI-98854 80 mg · Mixed Models Analysis · p = 0.2052 · Mean difference (net): -0.3 · 95% CI -0.7 to 0.2
SecondaryChange From Baseline to Last Visit in the Rush Video-based Tic Rating Scale (RTRS) Total Score

A modified RTRS was used in this study that includes short video recordings to measure 5 tic variables: number of body areas affected, frequency of motor and phonic tics, and severity of motor and phonic tics. The RTRS total score is calculated as the sum of the 5 domain scores, and ranges from 0 to 20, with higher scores representing greater severity. The final on-treatment visit was used in subjects who discontinued prior to Week 8.

Time frame:
Baseline, Week 8
Reported as:
Least squares mean · score on a scale
Change From Baseline to Last Visit in the Rush Video-based Tic Rating Scale (RTRS) Total Score
score on a scalePlaceboNBI-98854 40 mgNBI-98854 80 mg
Change From Baseline to Last Visit in the Rush Video-based Tic Rating Scale (RTRS) Total Score-1.9 ± 0.7-3.0 ± 0.6-3.6 ± 0.6
Statistical analysis
  • Placebo vs NBI-98854 40 mg · ANCOVA · p = 0.2215 · Mean difference (net): -1.0 · 95% CI -2.7 to 0.6
  • Placebo vs NBI-98854 80 mg · ANCOVA · p = 0.0566 · Mean difference (net): -1.6 · 95% CI -3.3 to 0.0
SecondaryChange From Baseline to Week 8 in the YGTSS Global Tic Severity Score

The YGTSS Global Tic Severity score is the sum of the YGTSS TTS and the YGTSS Impairment score and ranges from 0 to 100, with higher scores representing greater severity.

Time frame:
Baseline, Week 8
Reported as:
Least squares mean · score on a scale
Change From Baseline to Week 8 in the YGTSS Global Tic Severity Score
score on a scalePlaceboNBI-98854 40 mgNBI-98854 80 mg
Change From Baseline to Week 8 in the YGTSS Global Tic Severity Score-15.0 ± 2.6-16.2 ± 3.5-19.1 ± 2.9
Statistical analysis
  • Placebo vs NBI-98854 40 mg · Mixed Models Analysis · p = 0.5689 · Mean difference (net): -2.2 · 95% CI -9.8 to 5.4
  • Placebo vs NBI-98854 80 mg · Mixed Models Analysis · p = 0.2320 · Mean difference (net): -4.8 · 95% CI -12.8 to 3.1
SecondaryChange From Baseline to Week 8 in the Premonitory Urge for Tics Scale (PUTS) Total Score

The PUTS is an instrument for quantifying the premonitory urge phenomena associated with tics. It consists of 9 items, each of which is scored on a 4-point scale (1=not at all true, 2=a little true, 3=pretty much true, 4=very much true). The PUTS total score is calculated as the sum of the scores for the 9 items. The maximum possible total score is 36.

Time frame:
Baseline, Week 8
Reported as:
Least squares mean · score on a scale
Change From Baseline to Week 8 in the Premonitory Urge for Tics Scale (PUTS) Total Score
score on a scalePlaceboNBI-98854 40 mgNBI-98854 80 mg
Change From Baseline to Week 8 in the Premonitory Urge for Tics Scale (PUTS) Total Score-1.2 ± 0.7-0.8 ± 0.9-0.6 ± 0.9
Statistical analysis
  • Placebo vs NBI-98854 40 mg · Mixed Models Analysis · p = 0.4515 · Mean difference (net): -0.8 · 95% CI -3.0 to 1.3
  • Placebo vs NBI-98854 80 mg · Mixed Models Analysis · p = 0.6289 · Mean difference (net): -0.5 · 95% CI -2.8 to 1.7

Adverse events

Collected over Up to 10 Weeks. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Placebo0/40 (0%)1/40 (2.5%)8/40 (20%)
NBI-98854 40 mg0/42 (0%)1/42 (2.4%)22/42 (52.4%)
NBI-98854 80 mg0/42 (0%)2/42 (4.8%)32/42 (76.2%)
Most frequent serious events
Most frequent serious events
EventPlaceboNBI-98854 40 mgNBI-98854 80 mg
Pelvic inflammatory diseaseInfections and infestations1/400/420/42
Septic shockInfections and infestations0/401/420/42
HypersensitivityImmune system disorders0/400/421/42
Brachial plexus injuryInjury, poisoning and procedural complications0/401/420/42
Pneumonia streptococcalInfections and infestations0/401/420/42
Renal failure acuteRenal and urinary disorders0/401/420/42
PneumothoraxRespiratory, thoracic and mediastinal disorders0/400/421/42
Most frequent other events
Showing 10 of 13
Most frequent other events
EventPlaceboNBI-98854 40 mgNBI-98854 80 mg
AkathisiaNervous system disorders0/401/4210/42
SomnolenceNervous system disorders1/408/429/42
FatigueGeneral disorders1/405/427/42
HeadacheNervous system disorders2/406/422/42
InsomniaPsychiatric disorders0/400/425/42
SedationNervous system disorders1/401/424/42
AnxietyPsychiatric disorders1/401/424/42
NauseaGastrointestinal disorders1/401/424/42
Upper respiratory tract infectionInfections and infestations3/403/422/42
LethargyNervous system disorders0/402/423/42

Baseline characteristics

the intent-to-treat (ITT) analysis set, that includes all randomized subjects who received at least one dose of study drug, have postbaseline safety data \& have at least one post randomization Yale Global Tic Severity Scale (YGTSS) Total Tic Score (TTS) value at a scheduled visit or mapped early termination (ET) visit during 8-week treatment period

Age, Continuous
Age, Continuous(years)PlaceboNBI-98854 40 mgNBI-98854 80 mgTotal
Mean37.2 (18 to 62)34.1 (18 to 64)34.1 (18 to 61)35.1 (18 to 64)
Sex: Female, Male
Sex: Female, Male(Participants)PlaceboNBI-98854 40 mgNBI-98854 80 mgTotal
Female1691540
Male23322580
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)PlaceboNBI-98854 40 mgNBI-98854 80 mgTotal
Hispanic or Latino3249
Not Hispanic or Latino363936111
Unknown or Not Reported0000
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)PlaceboNBI-98854 40 mgNBI-98854 80 mgTotal
Race — American Indian or Alaska Native0000
Race — Asian1012
Race — Black or African American2215
Race — White343934107
Race — Native Hawaiian or Other Pacific Islander0000
Race — Other0000
Race — American Indian or Alaska Native, White2013
Race — Black or African American, White0011
Race — White, Other: German0011
Race — Other: Thai/White0011
Body mass index (BMI) at Screening
Body mass index (BMI) at Screening(kg/m^2 (kilogram/meter^2))PlaceboNBI-98854 40 mgNBI-98854 80 mgTotal
Mean28.69 (18.8 to 40.0)28.75 (19.2 to 38.3)29.01 (18.2 to 43.5)28.82 (18.2 to 43.5)
Yale Global Tic Severity Scale (YGTSS) Total Tic Score (TTS)
Yale Global Tic Severity Scale (YGTSS) Total Tic Score (TTS)(Score on scale)PlaceboNBI-98854 40 mgNBI-98854 80 mgTotal
Mean32.1 (16 to 47)31.6 (17 to 45)30.0 (19 to 45)31.2 (16 to 47)
08

Study locations

30 sites
  • Long Beach, California, United States
  • National City, California, United States
  • San Bernardino, California, United States
  • San Diego, California, United States
  • Upland, California, United States
  • Gainesville, Florida, United States
  • Hialeah, Florida, United States
  • Saint Petersburg, Florida, United States
  • Tampa, Florida, United States
  • Atlanta, Georgia, United States
  • Chicago, Illinois, United States
  • Boston, Massachusetts, United States
  • Natick, Massachusetts, United States
  • Saint Louis, Missouri, United States
  • Nashua, New Hampshire, United States
  • Summit, New Jersey, United States
  • Albany, New York, United States
  • Manhasset, New York, United States
  • New York, New York, United States
  • Staten Island, New York, United States
  • Cincinnati, Ohio, United States
  • Oklahoma City, Oklahoma, United States
  • Norristown, Pennsylvania, United States
  • Nashville, Tennessee, United States
  • Dallas, Texas, United States
  • Irving, Texas, United States
  • Orem, Utah, United States
  • Salt Lake City, Utah, United States
  • Kirkland, Washington, United States
  • Spokane, Washington, United States
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Nov 2015 to primary completion in Dec 2016, 13 months.

Results were first posted in May 2020, 3 years 5 months after primary completion.

Of 19 phase 2 interventional studies under Tourette Syndrome, half reached primary completion within 25 months of starting (the median), counting those still running; a quarter within 15 and three quarters within 42. This study's 13 months is below that.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 19, 2015
First posted
Oct 21, 2015
StartActual
Nov 2015
Primary completionActual
Dec 2016
CompletionActual
Dec 2016
Results first posted
May 7, 2020
Last update
May 7, 2020
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 7, 2020, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT02581865
Responsible party
Sponsor
First posted
Oct 21, 2015
Start date
Nov 2015
Primary completion
Dec 2016
Completion
Dec 2016
Results posted
May 7, 2020
Last update
May 7, 2020
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Apr 2020. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Valbenazine

Start the discussion